Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Wilkinson, S. Sherlock.
The effect of repeated albumin infusions in patients with cirrhosis.
Lancet, ii (1962), pp. 125-128
[2.]
J.H. Starling.
Contribution to the physiology of lymph secretion.
J Physiol (Lond), 14 (1893), pp. 131-153
[3.]
M.H. Witte, C.I. Witte, A.E. Dumont.
Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites.
Gastroenterology, 61 (1971), pp. 742-750
[4.]
S. Papper, J.L. Belsky, K.H. Bleifer.
Renal failure in Laennec’s cirrhosis of the liver. Description of clinical and laboratory features.
Ann Intern Med, 51 (1959), pp. 759-773
[5.]
F.L. Lieberman, E.K. Denison, T.B. Reynolds.
The relationship of plasma volume, portal hypertension, ascites and renal sodium and water retention in cirrhosis: the «overflow» theory of ascites formation.
Ann NY Acad Sci, 170 (1970), pp. 202-206
[6.]
R.W. Schrier, V. Arroyo, M. Bernard, M. Epstein, J.H. Henriksen, J. Rodés.
Peripheral arterial vasodilatation hypothesis, a proposal for the initiation of renal sodium and water retention in cirrhosis.
Hepatology, 8 (1988), pp. 1151-1157
[7.]
P. Ginés, V. Arroyo, E. Quintero, et al.
Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascitis. Results of a randomized study.
Gastroenterology, 93 (1987), pp. 234-241
[8.]
P. Sort, M. Navasa, V. Arroyo, et al.
Effect of plasma volume expansion on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
N Engl J Med, 341 (1999), pp. 403-409
[9.]
P. Ginés, R. Ortega, J. Uriz, et al.
Effect of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase II study [abstract].
Hepatology, 34 (2001), pp. A186
[10.]
S.S. Award, S. Sawada, O.S. Solders, et al.
Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemofiltration system?.
ASAIO J, 45 (1999), pp. 47-49
[11.]
J.H. Henrikse, F. Bendtsen, T.I. Sorensen, C. Stadeager, H. Ringlarsen.
Reduced central blood volume in cirrhosis.
Gastroenterology, 97 (1989), pp. 1506-1513
[12.]
A. Ginés, G. Fernández-Esparrach, A. Monescillo, et al.
Randomized trial compared albumin, dextran 70 and polygelin in cirrhotic patients with ascitis treated by paracentesis.
Gastroenterology, 111 (1996), pp. 1002-1010
[13.]
M. Navasa, A. Rimola, J. Rodés.
Bacterial infections in liver disease.
Semin Liver Dis, 17 (1997), pp. 323-333
[14.]
R. Ortega, P. Ginés, J. Uriz, et al.
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome results of a prospective, nonrandomized study.
Hepatology, 36 (2001), pp. 941-948
[15.]
J. Stange, S. Mitzner, W. Ramlow, T. Gliesche, H. Hickstein, R. Schmidt.
A new procedure for the removal of protein bound drugs and toxins.
ASAIO J, 39 (1993), pp. M621-M625
[16.]
S.R. Mitzner, J. Stange, S. Klammt, P. Pesynski, R. Smidt, G. Noldge-Schomburg.
Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.
J Am Soc Nephrol, 12 (2001), pp. S75-S82
[17.]
V. Arroyo.
Albumin in the treatment of liver diseases -new features of a classical treatment.
Aliment Pharmacol Ther, 16 (2002), pp. 1-5
[18.]
S.R. Mitzner, J. Stange, S. Klammt, et al.
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS. Results of a prospective, randomized, controlled clinical trial.
Liver Transplant, 6 (2000), pp. 277-286
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
